Standard Biotools (LAB) FCF Margin (2010 - 2026)

Standard Biotools (LAB) has reported FCF Margin for 17 consecutive years, with 53.0% the latest figure, recorded in Q2 2026.

• On a quarterly basis, FCF Margin rose 5064.0% year-over-year to 53.0% in Q2 2026; TTM through Jun 2026 was 97.61%, a 2108.0% increase from a year earlier, with the FY2025 full-year figure at 96.85%, up 6995.0% from the prior year.
• FCF Margin was 53.0% for Q2 2026 at Standard Biotools, up from 223.05% in the prior quarter.
• Over five years, FCF Margin peaked at 7.0% in Q4 2025 and troughed at 223.05% in Q1 2026.
• A 5-year average of 99.01% and a median of 87.34% in 2022 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin surged 12795 bps in 2023 and tumbled 14548 bps in 2024, its largest moves.
• Over 5 years, FCF Margin stood at 73.78% in 2022, then soared by 32 bps to 50.16% in 2023, then plunged by 40 bps to 70.39% in 2024, then soared by 90 bps to 7.0% in 2025, then plunged by 657 bps to 53.0% in 2026.
• The last three FCF Margin figures came in at 53.0% (Q2 2026), 223.05% (Q1 2026), and 7.0% (Q4 2025), per Business Quant data.